The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

* INCLUSION CRITERIA - FOR MALE COHORT: * Patients must have histologically or cytologically confirmed prostate cancer. Note: If histologic documentation is unavailable, a clinical course consistent with prostate cancer is acceptable. * Patients must be eligible for and must be planning to undergo androgen deprivation therapy * Testosterone levels greater than or equal to 100 ng/dL * Patients must have progressive prostate cancer as indicated by either prostate-specific antigen (PSA) progression (PSA progression is defined as two consecutively rising PSAs above the nadir post- definitive therapy and an absolute value greater than 1.0 ng/mL separated by at least 2 weeks) or radiographic progression based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or Prostate Cancer Working Group 3 (PCWG3). * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 * Patients must have normal organ and marrow function as defined below: * Hemoglobin greater than or equal to 9 g/dL * leukocytes greater than or equal to 3,000/mcL * absolute neutrophil count greater than or equal to 1,500/mcL * platelets greater than or equal to 150,000/mcL * total bilirubin within normal institutional limits * Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT)/alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) less than or equal to institutional upper limit of normal * creatinine within normal institutional limits OR creatinine clearance greater than or equal to 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal (calculated via Cockcroft-Gault equation) * Patients must not have other concurrent malignancies (within the past 2 years with the exception of non-melanoma skin cancer and Rai Stage 0 chronic lymphocytic leukemia), in situ carcinoma of any site, or life-threatening illnesses, including untreated infection (must be at least 1 week off intravenous antibiotic therapy before beginning zolpidem). * Ability of subject to understand and the willingness to sign a written informed consent document. * Ability to swallow study medication. * Willingness to travel to National Institutes of Health (NIH) for follow-up visits. * Men age greater than or equal to 18 years of age. Children are excluded because prostate cancer is not common in pediatric populations. INCLUSION CRITERIA - FOR NORMAL HEALTHY FEMALE COHORT: * Females age greater than or equal to 18 years of age * Good health conditions or without significant diseases, according to best medical judgement. * If breastfeeding, must be willing to discard breastmilk for 24 hours following zolpidem. * Ability if subject to understand and the willingness to sign a written informed consent Ability to swallow study medication. EXCLUSION CRITERIA - FOR MALE COHORT: * Patients who are receiving any other investigational agents (in the past 28 days) or herbal medications (within 1 day). * Patients who have received systemic chemotherapy for prostate cancer will not be eligible. * Known hypersensitivity to Zolpidem or chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug. * Clinically significant cardiac disease, e.g. New York Heart Association (NYHA) classes III-IV; uncontrolled angina, uncontrolled arrhythmia or uncontrolled hypertension, myocardial infarction in the previous 6 months as confirmed by an electrocardiogram (ECG). * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with zolpidem. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated. * Patients with known active treatment for Hepatitis B and C infections. * Patients who are taking medications that may alter the metabolism of zolpidem. This includes strong Cytochrome P450 3A4 (CYP3A4) inhibitors or inducers or CYP3A4 substrates with a narrow therapeutic index. For a current table of Substrates, Inhibitors and Inducers please access the following website: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm * History or presence of hepatic or gastrointestinal diseases, or other condition that interferes with drug absorption, distribution, excretion or metabolism. * Patients currently taking other sedative hypnotic medications Patients with a known history of psychiatric issues * Patients at risk for fall or who have had recent fractures * Patients of Asian descent EXCLUSION CRITERIA - FOR NORMAL HEALTHY FEMALE COHORT: * Chronic therapy with any drugs, except contraceptives * History of hepatic, kidney, lungs, gastrointestinal, epileptic, hematologic or psychiatric disease; hypotension or hypertension, of any etiology, that requires pharmacological treatment; history of myocardial infarction, angina and/or heart failure. * Use of regular medications within 2 weeks prior study enrollment or use of any medications within one week prior to study enrollment, except contraceptives or cases which, based on drugs or metabolites half-life, complete elimination can be assumed. * Hospitalization for any reason up to 8 weeks before enrollment. * Any condition, according to investigator's best judgement, that prevents the subject to participate in the trial * Pregnancy, labor or miscarriage within 12 weeks before admission predicted date. * Known hypersensitivity to zolpidem or chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug. Females of Asian descent -History of taking estrogen derivatives, androgens, or similar hormonal replacement or supplementation products. Past and current use of hormonal contraceptives is allowed.